Minecraft Gamers Can Now Earn Trilium From the Alien Worlds Metaverse
Minecraft, the best-selling video game in history engaging more than 170 million players, will be able to earn Trilium, the native cryptocurrency in the Alien Worlds metaverse. Alien Worlds is one of the largest play to earn (P2E) blockchain games and NFT metaverse.
Launched in 2020, Alien Worlds has grown to be the second largest blockchain platform by monthly active users. In the game, users can play with unique digital items (NFTs), stake Trilium tokens, travel on Alien Worlds Missions to other planets, vote in elections, and run for planetary council. The game’s 6 planet DAOs compete with each other for Trilium, encouraging user collaboration.
The new interoperability bridge to the world’s longest running and most popular online building platform will have resounding effects in the traditional and blockchain gaming worlds. The bridge will accelerate the onboarding of non-blockchain gamers onto the Alien Worlds metaverse, and also due to the open sourced nature of the code developed - empower other Minecraft servers to earn play-to-earn rewards. Plus, it will allow other blockchain projects to tap into Minecraft's vast user base.
Additionally, this interoperability will offer traditional gamers the opportunity to earn assets, in this case Trilium, and soon NFTs, for completing quests. Players are able to exchange their digital assets freely, enabling them to earn real world utility by getting involved in Alien Worlds’ simulated economy.
“This bridge is significant in that we are linking one of the world’s most popular decentralized games to the blockchain, and opening up a world of new possibilities for Minecraft players through our social metaverse,” says Alien Worlds co-founder Saro McKenna. “We think our combination of economics, team strategy and earning will convert Minecraft players of all ages into Web3 players.”
Additionally, earning Trilium will allow Minecraft gamers to stake the fungible token to one of the Alien Worlds Planet DAOs, which hold some of the largest treasuries in the space. Staked Trilium translates into voting power to determine control of planetary treasuries. Minecraft players will not only be able to learn about DAOs, but also to participate in the collaborative, competitive and highly strategic environment that their gamification entails.
About Alien Worlds
Alien Worlds is a breakthrough NFT Metaverse and one of the world’s most popular play-to-earn blockchain games, where users can play with unique digital assets (NFTs), stake Trilium tokens, travel on Missions to the planets, vote in elections, and run for planetary council. The game’s 6 planet DAOs compete with each other for Trilium, allowing users to collaborate, compete and strategize with one another.
With almost 7 million all-time players and more than 700,000 Monthly Active Users (number of unique wallet addresses interacting with Alien Worlds' smart contracts on a monthly basis, DappRadar), Alien Worlds has rapidly climbed the DappRadar ranking charts and inspired individuals to scale new heights of imagination in order to create, share and thrive in the Social Metaverse.
To access and play Alien Worlds and the new Alien Worlds Missions game, visit www.alienworlds.io, play.alienworlds.io/missions and the Explorers Station.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220328005182/en/
Contact information
Tonie Wells - tonie.wells@wachsman.com
+ 1 313 284-6270
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press Release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press Release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom